Erudio Healtherudio.com
Drug
Ipatasertib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying ipatasertib: CUPISCO. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 4 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| CUPISCO NCT03498521 · Hoffmann-La Roche | unfavourable cancer of unknown primary | Phase 2 | 358 | 62 | Deep | Oct 31, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ROME NCT04591431 · Fondazione per la Medicina Personalizzata DeepView → | advanced solid tumors | Phase 2 | Deep | View | |||
| IPATential150 NCT03072238 · Hoffmann-La Roche DeepView → | previously untreated metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| MORPHEUS-panBC NCT03424005 · Hoffmann-La Roche FocusedView → | metastatic breast cancer | Phase 1/Phase 2 | Focused | View | |||
| IPATunity130 NCT03337724 · Hoffmann-La Roche FocusedView → | PIK3CA/AKT1/PTEN-altered advanced HER2-negative breast cancer | Phase 3 | Focused | View | |||